Molecular Docking Study of Quercetin Analogues for Treating Tumours

S.Gejalakshmi1, N.Harikrishnan1

1Faculty of Pharmacy, Dr.M.G.R.Educational and Research Institute, Velappanchavadi, Chennai-77, India

Abstract: Drug discovery leading to robust and viable lead candidate’s remains a challenging scientific task, which is the transition from a screening hit to a drug candidate, requires expertise and experience. Natural products and their derivatives have been recognized for many years as a source of therapeutic agents and of structural diversity. The present research attempts to describe the utilization of compounds derived from natural resources as drug candidates, with a focus on the success of these resources in the process of finding and discovering new and effective drug compounds, an approach commonly referred to as “natural product drug discovery”.

Introduction:

Estrogen receptor alpha (ERα), also known as NR3A1 (nuclear receptor subfamily 3, group A, member 1), is one of two main types of estrogen receptor, a nuclear receptor that is activated by the sex hormone estrogen. In humans, ERα is encoded by the gene ESR1 (Estrogen Receptor 1).

The estrogen receptor (ER) exists in two forms known as ER alpha and ER beta. Currently, a clinical role has only been established for ER alpha. The primary use of ER alpha in breast cancer is for predicting likely response to hormone treatment. Patients with breast cancers expressing ER alpha are approximately seven to eight times more likely to benefit from endocrine therapy than ER alpha-negative patients. For the initial three to five years after primary diagnosis, ER alpha-positive patients generally have a better outcome than ER alpha-negative patients. Overall, however, the prognostic value of ER alpha is relatively weak and only of limited value in the clinically important subgroup of patients with lymph node-negative disease. Further work is required to establish if ER beta has a clinical role in breast cancer.

Estrogen receptors (ERs) are a group of proteins found inside cells. They are receptors that are activated by the hormone estrogen (17β-estradiol).

S.Gejalakshmi et al /International Journal of PharmTech Research, 2019,12(4): 30-34.
DOI: http://dx.doi.org/10.20902/IJPTR.2019.120405
Estrogen receptors are over-expressed in around 70% of breast cancer cases, referred to as "ER-positive", and can be demonstrated in such tissues using immunohistochemistry. Two hypotheses have been proposed to explain why this causes tumorigenesis, and the available evidence suggests that both mechanisms contribute:

- First, binding of estrogen to the ER stimulates proliferation of mammary cells, with the resulting increase in cell division and DNA replication, leading to mutations.
- Second, estrogen metabolism produces genotoxic waste.

**Human Epidermal Growth Factor Receptor**

**Description:**

The protein encoded by this gene is a transmembrane glycoprotein that is a member of the protein kinase superfamily. This protein is a receptor for members of the epidermal growth factor family. EGFR is a cell surface protein that binds to epidermal growth factor. Binding of the protein to a ligand induces receptor dimerization and tyrosine autophosphorylation and leads to cell proliferation.\(^{3-7}\)

Approximately half cases of triple-negative breast cancer (TNBC) and inflammatory breast cancer (IBC) overexpress EGFR. Thus, EGFR inhibitors for treatment of breast cancer have been evaluated in several studies.\(^8\)

**Drug Likeness Testing**\(^9-13:\)

DruLiTo was used to test the drug likeness property of the molecule, the results are tabulated as follows:

| Selected Filters            | Total Number of Molecule Violated the Rule |
|-----------------------------|--------------------------------------------|
| Lipinskies Rule of Five     | 0                                          |
| Ghose Filter                | 0                                          |
| CMC – 50 Like Rule          | 0                                          |
| Vebers Rule                 | 1                                          |
| MDDR Like Rule              | 1                                          |
| BBB Likeness Rule           | 1                                          |
| Unweighted QED              | 0                                          |

**Receptor preparation:**

The well-defined 3d structure of Estrogen receptor alpha ligand-binding domain complexed to estradiol was download from RCSB PDB (http://www.rcsb.org). It consist of code 1A52. Receptor structure is downloaded in pdb format so as to view in Argus lab.

**Ligand preparation:**

Bioactive quercetin compound is obtained from *Hypericum formosanum* was selected as ligand for receptor Estrogen receptor alpha ligand-binding domain complexed to estradiol. The ligand structure is drawn using chemsketch software, its 3d structure viewed in Argus lab.

**Molecular docking:**

Initially some active sites of receptor Estrogen receptor alpha ligand-binding domain complexed to estradiol were identified such as 380GLU, 520LYS, 526TYR, 632TRP, 716ARG based on earlier studies. The docking study was made on ArgusLab 4.0.1 from Mark Thompson and Planariasoftware LLC. The docking is studied in grid dimension (x, y, z) of 39 x 39 x 39. The docking study is analysed in basis of best ligand pose and are active sites are ranked on basis of it. Further dockings were visualized in Pymol viewer.
| S.No | Rank | Active Site | Best Ligand Pose Energy (KCal/Mol) | Cluster Poses |
|------|------|-------------|-----------------------------------|---------------|
| 1    | 1    | 632TRP      | -7.21194                          | 86            |
| 2    | 2    | 380GLU      | -6.6713                           | 94            |
| 3    | 3    | 520LYS      | -6.3629                           | 62            |
| 4    | 4    | 526TYR      | -6.22825                          | 109           |
| 5    | 5    | 716ARG      | -6.17315                          | 95            |
Molecular study is mainly to predict the specific ligand interaction and binding energy with amino acid of receptor. Docking study is made with help of Argulab software, automated docking made with selected amino acids which gives the binding poses energy (Kcal/mol). Lowest bind energy is considered as best binding area. Quercetin ligand binds with an amino acids such as 632 TRP, 380 GLU, 520 LYS, 526 TYR, 716 ARG with binding poses energy of -7.211, -6.671, -6.362, -6.228, -6.173 respectively. From the docking study, quercetin is binded with receptor 1A52, Therefore it may use for synthesis of anticancer.

Conclusion:

The result of docking study shows that the quercetin obtained from extraction of Hypericumformosanum can be use for reduction of cancer. The aromatic aldehyde derivative formed between Gly238 and hydroxyl of aldehyde of chromones, the bond length was found to be -1.1 near aromatic substitution of chromone substitution. The aromatic aldehyde derivative formed between Phe239 and hydroxyl of aldehyde of chromones, the bond length was found to be 1.4A near aromatic substitution of chromone substitution. The other hydrogen was found between Ly2 and hydroxy group of chromonederivatives. The bond length was found to be—4.8 A aromatic substitution of chromonederivatives. The active site is present in A ring of the protein. The residue bind with the ligand is same as that of the standard compounds docked. The residues found in the active sites are as follows 632 TRP, 380 GLU, 520 LYS, 526 TYR, 716 ARG.

Ligand: Quercetin

References

1. Chakraborty R and Rajagopalan R. Diabetes and insulin resistance associated disorders: disease and the therapy Current Science 2002, 83, 1533-1538.
2. Beghyn T, Deprez-poulain R, Willcand N, Folleas B and Deprez B, Natural compounds: lead or ideas Bio inspired molecules for drug discovery Chem. Biol. Drug Discovery, 2008, 72(1), 3-15.
3. KameswaraRao B, RenukaSudarshan P, Rajasekhar MD, Nagaraju N and AppaRao CH, Hypoglycemic activity of Terminaliapallida fruit in alloxan induced diabetic rats. J. Ethnopharmacology 2003, 85, 169-172.
4. ParulLakhanpal, MD and Dr. Deepak Kumar Rai MD, Quercetin: A Versatile Flavonoid Internet Journal of Medical Update 2007, 2(2), 345-347.
5. Muhammad SA and Fatima N. In silico analysis and molecular docking studies of potential angiotensin-converting enzyme inhibitor using quercetin glycosides Pharmaconosy Magazine 2015, 11(1), 123-126.
6. Tomar NR, Singh V, Marla SS, Chandra R, Kumar R, Kumar A Molecular docking studies with rabies virus glycoprotein to design viral therapeutics Indian J Pharm Sci. 2010 Jul;72(4):486-90
7. Hanaa A, TawfikEwies and Wageeh S and El-Hamouly Synthesis of chromones and their applications during the last ten years IJRPC 2014, 4(4),1046-1085
8. KrutikaThorat, LeenaPatil, DnyaneshLimaye and VilasraoKadamKadam, Invitro Models for Antidiabetic Activity Assessment International Journal of Research in Pharmaceutical and Biomedical Sciences 2012, 3 (2), 730-733
9. Artanti N, Firmansyah T and Darmawan A, Bioactivities Evaluation of Indonesian Mistletoes (Dendrophthoepentandra(L.) Miq.) Leaves Extracts J.Appl. Pharma. Sci. 2012, 2 (01), 24- 27
10. Mona F Mahmoud, Noura A, Hassan, Hany E1, Bassossy, Ahmed Fahmy, Quercetin protects against diabetes-induced exaggerates vasoconstriction in rats: effect on low grade inflammation. Plos one 2013, 8 (5), 367-369.

11. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69–90, doi: 10.3322/caac.20107.

12. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87–108, doi: 10.3322/caac.21262.

13. Zhang H, Stephens LC, Kumar R. Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer. Clin Cancer Res 2006; 12: 1479–1486, doi: 10.1158/1078-0432.CCR-05-1519.